{"transactions":[{"id":713056,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":31508,"kind":"person","name":"Coffey Steven R. S.","position":1,"cik":"0002121676","reported_name":"Coffey Steven R. S.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-08T20:59:30.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."}],"balance_after":100000,"derivative":{"exercise_price":9.1,"underlying":"ADSs","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-076431","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026076431/ownership.xml","form_type":"4"}},{"id":713054,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":31506,"kind":"person","name":"Friend John E. II","position":1,"cik":"0001704021","reported_name":"Friend John E. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Share Units","published_at":"2026-07-08T20:59:05.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents a board-approved award of 150,000 restricted share units (\"RSUs\"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a board-approved award of 150,000 restricted share units (\"RSUs\"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents a board-approved award of 150,000 restricted share units (\"RSUs\"), approved by the Remuneration Committee on January 8, 2026. One-third of the RSUs vest on January 8, 2027, and the remaining two-thirds vest in equal yearly tranches thereafter. Each RSU represents a contingent right to receive one ADS of the Issuer."}],"balance_after":150000,"derivative":{"underlying":"ADSs","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-26-076430","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026076430/ownership.xml","form_type":"4"}},{"id":713053,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":31506,"kind":"person","name":"Friend John E. II","position":1,"cik":"0001704021","reported_name":"Friend John E. II","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-08T20:59:05.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents a board-approved award of 500,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."}],"balance_after":500000,"derivative":{"exercise_price":6.78,"underlying":"ADSs","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001213900-26-076430","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026076430/ownership.xml","form_type":"4"}},{"id":713052,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":31505,"kind":"person","name":"Bonacorda Jeffrey","position":1,"cik":"0002115111","reported_name":"Bonacorda Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"VP, Finance and Controller"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-08T20:58:37.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents a board-approved award of 150,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."}],"balance_after":150000,"derivative":{"exercise_price":6.78,"underlying":"ADSs","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001213900-26-076429","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026076429/ownership.xml","form_type":"4"}},{"id":713051,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":31504,"kind":"person","name":"Davidson Ebru","position":1,"cik":"0002135805","reported_name":"Davidson Ebru","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-08T20:58:10.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."}],"balance_after":100000,"derivative":{"exercise_price":9.1,"underlying":"ADSs","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-076428","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026076428/ownership.xml","form_type":"4"}},{"id":713049,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":31502,"kind":"person","name":"Cain David","position":1,"cik":"0002125950","reported_name":"Cain David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Director, CMC"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-08T20:57:45.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents a board-approved award of 100,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $9.10 per ADS. The exercise price for Australian resident participants reflects Australian tax considerations applicable to grants under the Issuer's employee share plan. One-third of the options vest on January 8, 2027 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. The options were granted for no consideration and expire on January 8, 2029."}],"balance_after":100000,"derivative":{"exercise_price":9.1,"underlying":"ADSs","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001213900-26-076427","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026076427/ownership.xml","form_type":"4"}},{"id":713050,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":31503,"kind":"person","name":"APPLE ROBERT F","position":1,"cik":"0001054942","reported_name":"APPLE ROBERT F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-07-08T20:57:19.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents a board-approved award of 75,000 options over ADSs, approved by the Remuneration Committee on January 8, 2026, at an exercise price of $6.78 per ADS, which was set by reference to the closing price of the Issuer's ADSs on Nasdaq on January 8, 2026. The options vest on January 8, 2027. The options were granted for no consideration and expire on January 8, 2029."}],"balance_after":75000,"derivative":{"exercise_price":6.78,"underlying":"ADSs","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001213900-26-076426","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026076426/ownership.xml","form_type":"4"}},{"id":729513,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":36097,"kind":"person","name":"Levine James E.","position":1,"cik":"0001463151","reported_name":"Levine James E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-23T22:47:31.000Z","date":"2026-06-19","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of 200,000 options over ADSs on June 19, 2026, at an exercise price of $13.86 per ADS. One-third of the options vest on June 1, 2026 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029."}],"balance_after":200000,"derivative":{"exercise_price":13.86,"underlying":"ADSs","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001213900-26-071231","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026071231/ownership.xml","form_type":"4"}},{"id":729512,"issuer":{"id":6537,"kind":"organization","name":"KAZIA THERAPEUTICS LTD"},"owners":[{"id":36096,"kind":"person","name":"Rao Sudha","position":1,"cik":"0002132027","reported_name":"Rao Sudha","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-06-23T22:47:16.000Z","date":"2026-06-19","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents the grant to the Reporting Person of 250,000 options over ADSs at an exercise price of $18.48 per ADS. One-third of the options vest on April 13, 2026 (the \"Commencement Date\") and the remaining two-thirds vest in equal yearly tranches on the anniversary of the Commencement Date. All options held by the Reporting Person will be forfeited upon the Reporting Person's voluntary departure prior to the first anniversary of the Commencement Date. The options were granted for no consideration and expire on June 19, 2029."}],"balance_after":250000,"derivative":{"exercise_price":18.48,"underlying":"ADSs","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001213900-26-071230","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1075880/000121390026071230/ownership.xml","form_type":"4"}}]}